Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation
Objective: Extracorporeal circulation procedures have been shown to induce complement and leukocyte activation, release of endotoxin and inflammatory mediators, including cytokines, nitric oxide, oxygen free radicals, and platelet activating factors. The contact between the blood and the various art...
Saved in:
Published in | European journal of cardio-thoracic surgery Vol. 16; no. 3; pp. 342 - 350 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier Science B.V
01.09.1999
Elsevier Science |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective: Extracorporeal circulation procedures have been shown to induce complement and leukocyte activation, release of endotoxin and inflammatory mediators, including cytokines, nitric oxide, oxygen free radicals, and platelet activating factors. The contact between the blood and the various artificial surfaces of the extracorporeal system results in an unspecific post-perfusion syndrome. For diminishing these negative side effects several coating-techniques have been developed to create devices with improved hemocompatibility. Methods: This review deals with the current knowledge of heparin-coated and otherwise surface-modified perfusion systems. The pathway how heparin-coated surfaces work is discussed and techniques for surface-coatings, both clinically introduced as well as newly developed are presented. Results: Numerous clinical studies compared heparin-coated versus non-coated circuits. Heparin-bonded devices showed lessened humoral and cellular activation, in particular a reduced complement activation with a reduced inflammatory post-perfusion syndrome. Also platelet protection and more favorable post-operative lung function are of particular note. Recent clinical trials demonstrated shortened hospital stays, less drainage bleeding, and reduced cerebral complications using heparin-coated oxygenation systems. The diminished expression of the leukocyte adhesion molecules CD 11b/c in CBAS devices points to a decreased activation of neutrophils. In addition, one research group found a reduced production of oxygen radicals. Heparin-bonding minimizes oxygenator failure by a significant reduced pressure gradient across the oxygenator, probably caused by decreased fibrin and platelet deposition at the hollow fiber surfaces. A meta analysis examined the impact of heparin-bonded systems on clinical outcomes and resulting costs. Using heparin-bonded circuits led to total cost savings from US $ 1000 to 3000. Several authors demonstrated reduced blood loss and better clinical outcome by reduction of systemic heparinization and the employment of heparin-coated devices. Conclusion: Above and beyond the long-term applications, routine heart operations have also markedly begun to utilize heparin-coated devices. This trend will assuredly continue in the coming years and is an important step toward higher hemocompatibility of blood-contacting surfaces in the ECC device. Heparin-coatings are merely the beginning of improved hemocompatibility for all materials that come into contact with human blood or tissues. Intelligent materials with almost completely physiological surfaces will be at the surgeon's disposal within the next few years. |
---|---|
AbstractList | Extracorporeal circulation procedures have been shown to induce complement and leukocyte activation, release of endotoxin and inflammatory mediators, including cytokines, nitric oxide, oxygen free radicals, and platelet activating factors. The contact between the blood and the various artificial surfaces of the extracorporeal system results in an unspecific post-perfusion syndrome. For diminishing these negative side effects several coating-techniques have been developed to create devices with improved hemocompatibility.
This review deals with the current knowledge of heparin-coated and otherwise surface-modified perfusion systems. The pathway how heparin-coated surfaces work is discussed and techniques for surface-coatings, both clinically introduced as well as newly developed are presented.
Numerous clinical studies compared heparin-coated versus non-coated circuits. Heparin-bonded devices showed lessened humoral and cellular activation, in particular a reduced complement activation with a reduced inflammatory post-perfusion syndrome. Also platelet protection and more favorable post-operative lung function are of particular note. Recent clinical trials demonstrated shortened hospital stays, less drainage bleeding, and reduced cerebral complications using heparin-coated oxygenation systems. The diminished expression of the leukocyte adhesion molecules CD 11b/c in CBAS devices points to a decreased activation of neutrophils. In addition, one research group found a reduced production of oxygen radicals. Heparin-bonding minimizes oxygenator failure by a significant reduced pressure gradient across the oxygenator, probably caused by decreased fibrin and platelet deposition at the hollow fiber surfaces. A meta analysis examined the impact of heparin-bonded systems on clinical outcomes and resulting costs. Using heparin-bonded circuits led to total cost savings from US $1000 to 3000. Several authors demonstrated reduced blood loss and better clinical outcome by reduction of systemic heparinization and the employment of heparin-coated devices.
Above and beyond the long-term applications, routine heart operations have also markedly begun to utilize heparin-coated devices. This trend will assuredly continue in the coming years and is an important step toward higher hemocompatibility of blood-contacting surfaces in the ECC device. Heparin-coatings are merely the beginning of improved hemocompatibility for all materials that come into contact with human blood or tissues. Intelligent materials with almost completely physiological surfaces will be at the surgeon's disposal within the next few years. Objective: Extracorporeal circulation procedures have been shown to induce complement and leukocyte activation, release of endotoxin and inflammatory mediators, including cytokines, nitric oxide, oxygen free radicals, and platelet activating factors. The contact between the blood and the various artificial surfaces of the extracorporeal system results in an unspecific post-perfusion syndrome. For diminishing these negative side effects several coating-techniques have been developed to create devices with improved hemocompatibility. Methods: This review deals with the current knowledge of heparin-coated and otherwise surface-modified perfusion systems. The pathway how heparin-coated surfaces work is discussed and techniques for surface-coatings, both clinically introduced as well as newly developed are presented. Results: Numerous clinical studies compared heparin-coated versus non-coated circuits. Heparin-bonded devices showed lessened humoral and cellular activation, in particular a reduced complement activation with a reduced inflammatory post-perfusion syndrome. Also platelet protection and more favorable post-operative lung function are of particular note. Recent clinical trials demonstrated shortened hospital stays, less drainage bleeding, and reduced cerebral complications using heparin-coated oxygenation systems. The diminished expression of the leukocyte adhesion molecules CD 11b/c in CBAS devices points to a decreased activation of neutrophils. In addition, one research group found a reduced production of oxygen radicals. Heparin-bonding minimizes oxygenator failure by a significant reduced pressure gradient across the oxygenator, probably caused by decreased fibrin and platelet deposition at the hollow fiber surfaces. A meta analysis examined the impact of heparin-bonded systems on clinical outcomes and resulting costs. Using heparin-bonded circuits led to total cost savings from US $ 1000 to 3000. Several authors demonstrated reduced blood loss and better clinical outcome by reduction of systemic heparinization and the employment of heparin-coated devices. Conclusion: Above and beyond the long-term applications, routine heart operations have also markedly begun to utilize heparin-coated devices. This trend will assuredly continue in the coming years and is an important step toward higher hemocompatibility of blood-contacting surfaces in the ECC device. Heparin-coatings are merely the beginning of improved hemocompatibility for all materials that come into contact with human blood or tissues. Intelligent materials with almost completely physiological surfaces will be at the surgeon's disposal within the next few years. OBJECTIVEExtracorporeal circulation procedures have been shown to induce complement and leukocyte activation, release of endotoxin and inflammatory mediators, including cytokines, nitric oxide, oxygen free radicals, and platelet activating factors. The contact between the blood and the various artificial surfaces of the extracorporeal system results in an unspecific post-perfusion syndrome. For diminishing these negative side effects several coating-techniques have been developed to create devices with improved hemocompatibility.METHODSThis review deals with the current knowledge of heparin-coated and otherwise surface-modified perfusion systems. The pathway how heparin-coated surfaces work is discussed and techniques for surface-coatings, both clinically introduced as well as newly developed are presented.RESULTSNumerous clinical studies compared heparin-coated versus non-coated circuits. Heparin-bonded devices showed lessened humoral and cellular activation, in particular a reduced complement activation with a reduced inflammatory post-perfusion syndrome. Also platelet protection and more favorable post-operative lung function are of particular note. Recent clinical trials demonstrated shortened hospital stays, less drainage bleeding, and reduced cerebral complications using heparin-coated oxygenation systems. The diminished expression of the leukocyte adhesion molecules CD 11b/c in CBAS devices points to a decreased activation of neutrophils. In addition, one research group found a reduced production of oxygen radicals. Heparin-bonding minimizes oxygenator failure by a significant reduced pressure gradient across the oxygenator, probably caused by decreased fibrin and platelet deposition at the hollow fiber surfaces. A meta analysis examined the impact of heparin-bonded systems on clinical outcomes and resulting costs. Using heparin-bonded circuits led to total cost savings from US $1000 to 3000. Several authors demonstrated reduced blood loss and better clinical outcome by reduction of systemic heparinization and the employment of heparin-coated devices.CONCLUSIONAbove and beyond the long-term applications, routine heart operations have also markedly begun to utilize heparin-coated devices. This trend will assuredly continue in the coming years and is an important step toward higher hemocompatibility of blood-contacting surfaces in the ECC device. Heparin-coatings are merely the beginning of improved hemocompatibility for all materials that come into contact with human blood or tissues. Intelligent materials with almost completely physiological surfaces will be at the surgeon's disposal within the next few years. |
Author | Ziemer, Gerhard Wendel, Hans Peter |
Author_xml | – sequence: 1 givenname: Hans Peter surname: Wendel fullname: Wendel, Hans Peter email: hp.wendel@uni-tuebingen.de organization: Division of Thoracic, Cardiac and Vascular Surgery, Department of Surgery, Eberhard-Karls-University, Hoppe-Seyler-Strasse 3, 72076 Tuebingen, Germany – sequence: 2 givenname: Gerhard surname: Ziemer fullname: Ziemer, Gerhard organization: Division of Thoracic, Cardiac and Vascular Surgery, Department of Surgery, Eberhard-Karls-University, Hoppe-Seyler-Strasse 3, 72076 Tuebingen, Germany |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1986235$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10554855$$D View this record in MEDLINE/PubMed |
BookMark | eNptkF1vFCEYhYmpsR_6EzRzYUy9QGEYYLisa-ua1BjTmmy8IQwfLjozjMA07b-X7axfiTe8kPc5nJxzDA7GMFoAnmL0CiPMXl-VE0EuGnQqxEuE6vISD8ARbjmBnDSbg3L_hRyC45S-IYQYqfkjcIgRpU1L6REYVkFlP36F2ert6H_MNlU5VH6YYrixVd7aamuHoMMwFa7zvc93VXCVitk7r73qK2NvvC6yOVlTuRAre5uj0iFOIdqy1z7quS_qMD4GD53qk32ynyfg88X59WoNLz--e786u4SaYZIhE52pCTVECWdFx3DXIat0bTTlbds2BhvqdN01uObUGMFLIVi7mvASXGFETsCL5d-SYhcpy8EnbftejTbMSTJRNwxhUkC6gDqGlKJ1cop-UPFOYiR3Pcv7nuWuRCmEvO9ZiqJ7tjeYu8Gav1RLsQV4vgdU0qp3UY3apz-caFlJWDC0YGGe_m8N_7GGO2u4SHzK9va3SMXvknHCqVxvvsiL9fWHt5s3V_IT-Qk5Kqbj |
CODEN | EJCSE7 |
CitedBy_id | crossref_primary_10_1053_j_jvca_2012_02_001 crossref_primary_10_1021_acs_biomac_6b00019 crossref_primary_10_1097_AIA_0000000000000381 crossref_primary_10_1177_0267659108093879 crossref_primary_10_1002_rth2_12346 crossref_primary_10_3390_membranes11080617 crossref_primary_10_1016_j_colsurfb_2010_04_013 crossref_primary_10_1016_S0142_9612_01_00122_3 crossref_primary_10_1002_jbm_a_30519 crossref_primary_10_1002_jbm_b_34932 crossref_primary_10_4028_www_scientific_net_MSF_514_516_863 crossref_primary_10_1016_S0003_4975_03_00977_9 crossref_primary_10_1080_140174302762659076 crossref_primary_10_1016_j_biomaterials_2010_01_097 crossref_primary_10_1016_j_jss_2010_01_037 crossref_primary_10_1016_S0003_4975_02_03796_7 crossref_primary_10_1021_am300878z crossref_primary_10_1111_j_1582_4934_2003_tb00213_x crossref_primary_10_1016_j_colsurfb_2008_08_008 crossref_primary_10_1177_0883911505049653 crossref_primary_10_1007_s10047_015_0842_0 crossref_primary_10_1016_j_actbio_2012_07_020 crossref_primary_10_1106_DUYU_CEL6_529C_WUL9 crossref_primary_10_1007_s10856_015_5628_7 crossref_primary_10_1021_acs_jchemed_2c00208 crossref_primary_10_1371_journal_pone_0240117 crossref_primary_10_1016_j_msec_2014_05_070 crossref_primary_10_1111_aor_12335 crossref_primary_10_1021_acsami_1c01079 crossref_primary_10_1002_jbm_b_33154 crossref_primary_10_1016_j_colsurfb_2021_111624 crossref_primary_10_1111_j_1525_1594_2009_00791_x crossref_primary_10_1039_c3tb20425a crossref_primary_10_1097_01_TP_0000137324_87116_41 crossref_primary_10_31590_ejosat_1083112 crossref_primary_10_1177_039139880402700807 crossref_primary_10_1097_MAT_0000000000000841 crossref_primary_10_1016_j_annfar_2005_12_002 crossref_primary_10_1046_j_1525_1594_2003_07050_x crossref_primary_10_1177_039139880602900908 crossref_primary_10_1016_j_addr_2011_05_010 crossref_primary_10_1111_j_1540_8191_2006_00298_x crossref_primary_10_1002_adfm_201908963 crossref_primary_10_1007_s12034_023_03019_w crossref_primary_10_1177_0885328202017001596 crossref_primary_10_1163_1568562054798554 crossref_primary_10_1191_0267659104pf718oa crossref_primary_10_1016_S0003_4975_01_02466_3 crossref_primary_10_1039_C4LC00828F crossref_primary_10_1177_155698451000500608 crossref_primary_10_1191_0267659104pf737oa crossref_primary_10_1016_j_polymer_2006_01_084 crossref_primary_10_1111_aor_12744 crossref_primary_10_1163_156856200744192 crossref_primary_10_1111_j_1525_1594_2004_07312_x crossref_primary_10_3389_fcvm_2020_583289 crossref_primary_10_1016_S0141_8130_03_00072_2 crossref_primary_10_1007_BF02829429 crossref_primary_10_1177_03913988231223360 crossref_primary_10_1093_ckj_sfab185 crossref_primary_10_1097_00001721_200410000_00009 crossref_primary_10_1002_mabi_201700359 crossref_primary_10_1002_mrm_28363 crossref_primary_10_1111_j_1525_1594_2011_01291_x crossref_primary_10_1586_17434440_3_2_245 crossref_primary_10_1097_MAT_0b013e31820bffa9 crossref_primary_10_1016_j_athoracsur_2003_10_060 crossref_primary_10_1016_S0142_9612_03_00170_4 crossref_primary_10_1002_jbm_b_20028 crossref_primary_10_1002_jbm_a_31663 crossref_primary_10_1002_jbm_b_34085 crossref_primary_10_1177_026765910101600402 crossref_primary_10_1016_j_jtcvs_2010_02_034 crossref_primary_10_1586_17434440_2_4_473 crossref_primary_10_1016_j_biomaterials_2003_11_025 crossref_primary_10_1021_acsami_5b05287 crossref_primary_10_1067_mtc_2002_120334 crossref_primary_10_1097_00007890_200211270_00020 crossref_primary_10_1002_app_40772 crossref_primary_10_1016_j_avsg_2017_09_017 crossref_primary_10_1016_j_resuscitation_2005_07_027 crossref_primary_10_1067_mtc_2001_111205 crossref_primary_10_1177_0267659110373840 crossref_primary_10_1021_bm0344553 crossref_primary_10_1016_j_progpolymsci_2008_07_006 crossref_primary_10_1002_jbm_b_30614 crossref_primary_10_1021_ac015517n crossref_primary_10_1016_S0142_9612_02_00215_6 crossref_primary_10_1021_bc100267z crossref_primary_10_1097_MAT_0b013e3181ebb815 crossref_primary_10_1155_2015_412319 crossref_primary_10_1177_0267659107084146 crossref_primary_10_1191_0267659102pf526oa crossref_primary_10_1053_j_jvca_2008_02_004 crossref_primary_10_1016_j_bioadv_2022_212824 crossref_primary_10_1111_j_1525_1594_2010_01173_x crossref_primary_10_1016_j_jmatprotec_2008_04_007 crossref_primary_10_1055_s_0040_1708542 crossref_primary_10_1080_22201173_2012_10872841 crossref_primary_10_32322_jhsm_854196 crossref_primary_10_1016_S0003_4975_03_00338_2 crossref_primary_10_1097_01_MAT_0000123638_41808_59 crossref_primary_10_1177_112972980400500308 crossref_primary_10_1097_00002480_200209000_00008 crossref_primary_10_1097_CCM_0000000000001869 crossref_primary_10_1039_B921629D crossref_primary_10_1155_2007_29464 crossref_primary_10_1177_0267659113483802 crossref_primary_10_1038_ncomms3168 crossref_primary_10_1177_0267659113480401 crossref_primary_10_1016_j_mehy_2015_04_030 crossref_primary_10_1016_j_thromres_2009_01_010 crossref_primary_10_1161_CIRCULATIONAHA_104_525378 crossref_primary_10_1177_0267659113479135 crossref_primary_10_1515_BMT_2009_036 crossref_primary_10_1051_ject_201446130 crossref_primary_10_3390_pharmaceutics13091504 crossref_primary_10_3390_molecules24244630 crossref_primary_10_1177_0267659109353818 crossref_primary_10_1007_s00398_019_00348_z crossref_primary_10_1051_ject_201648162 crossref_primary_10_1016_j_actbio_2011_01_031 crossref_primary_10_1586_17434440_3_3_345 crossref_primary_10_3389_fmed_2022_854258 crossref_primary_10_1034_j_1399_3089_2001_00083_x crossref_primary_10_1007_s10047_009_0477_0 crossref_primary_10_1016_j_ahj_2005_03_067 crossref_primary_10_1007_s11886_018_1041_4 crossref_primary_10_7243_2052_4358_1_1 crossref_primary_10_1097_00002480_200211000_00005 crossref_primary_10_1186_s13019_020_01214_y crossref_primary_10_1191_0267659103pf681oa crossref_primary_10_1007_s10856_005_2541_5 crossref_primary_10_3389_fmed_2018_00321 crossref_primary_10_1002_jbm_a_31018 crossref_primary_10_1016_j_ejcts_2008_07_060 crossref_primary_10_1007_s13204_018_0693_0 crossref_primary_10_1021_ja020268l crossref_primary_10_1039_C4TB00881B crossref_primary_10_1097_00001721_200409000_00009 crossref_primary_10_4236_wjcs_2014_412034 crossref_primary_10_1016_j_biomaterials_2004_05_029 crossref_primary_10_1177_0267659112468014 crossref_primary_10_1038_s41390_023_02605_2 crossref_primary_10_1097_TA_0000000000002700 crossref_primary_10_1177_0267659111419990 crossref_primary_10_1016_j_chemosphere_2018_03_136 crossref_primary_10_1016_j_jtcvs_2004_01_041 crossref_primary_10_1111_aor_13521 crossref_primary_10_1016_j_addr_2016_12_002 crossref_primary_10_1002_mabi_200800150 crossref_primary_10_1007_s43153_023_00417_9 crossref_primary_10_1021_la200376f crossref_primary_10_1097_01_mat_0000169119_06419_ed crossref_primary_10_3390_jcm11175147 crossref_primary_10_1111_j_1525_1594_2010_01183_x crossref_primary_10_1016_j_biotechadv_2009_10_005 crossref_primary_10_3389_fped_2019_00366 crossref_primary_10_1016_j_biomaterials_2021_121011 crossref_primary_10_1016_j_memsci_2006_12_014 crossref_primary_10_1177_026765910101600605 crossref_primary_10_1021_la7002996 crossref_primary_10_3389_fmats_2022_877755 crossref_primary_10_1016_S1499_3872_13_60068_5 crossref_primary_10_1177_0885328211428525 crossref_primary_10_1159_000347222 crossref_primary_10_1177_0267659113475834 crossref_primary_10_4028_www_scientific_net_AMR_222_297 crossref_primary_10_1002_jbm_b_35130 crossref_primary_10_1177_02676591231177912 crossref_primary_10_1002_1097_4636_200107_56_1_1__AID_JBM1024_3_0_CO_2_C crossref_primary_10_1002_ppap_202200228 crossref_primary_10_1002_jemt_22172 crossref_primary_10_4161_org_7_1_14024 crossref_primary_10_1016_j_ijcard_2012_01_020 crossref_primary_10_1007_s10047_016_0887_8 crossref_primary_10_1002_jbm_b_10016 crossref_primary_10_1016_j_biomaterials_2004_01_023 crossref_primary_10_1021_acs_langmuir_3c00945 crossref_primary_10_1177_0885328214538866 crossref_primary_10_1002_jbm_b_31626 crossref_primary_10_1051_ject_200537023 crossref_primary_10_1016_j_apsusc_2014_01_048 crossref_primary_10_1051_ject_200537387 crossref_primary_10_1016_j_ppedcard_2019_101187 crossref_primary_10_1016_j_biomaterials_2003_12_014 crossref_primary_10_1007_s40610_016_0046_2 crossref_primary_10_4028_www_scientific_net_MSF_475_479_2391 crossref_primary_10_4161_org_7_1_14029 crossref_primary_10_1002_pi_2773 crossref_primary_10_3390_bioengineering10040411 |
Cites_doi | 10.1016/S0022-5223(19)34964-5 10.1016/S0003-4975(97)01347-7 10.1177/039139889702000109 10.1016/S0022-5223(96)70275-1 10.1016/0003-4975(96)00225-1 10.1016/S0003-4975(96)00964-2 10.3109/14017439509107224 10.3109/03009739209179282 10.1378/chest.112.3.676 10.1016/S0022-5223(96)70395-1 10.1016/S0022-5223(95)70117-6 10.1016/S0022-5223(95)70119-2 10.1177/026765919801300307 10.1016/0003-4975(95)00366-S 10.1016/S1053-0770(98)90010-6 10.1126/science.142.3597.1297 10.1177/026765919701200607 10.1097/00002480-199339030-00008 10.1016/S0003-4975(96)00743-6 10.1111/j.1525-1594.1997.tb03741.x 10.1177/039139889702000308 10.1016/S0022-5223(97)70373-8 10.1016/0003-4975(94)92213-6 10.1016/0003-4975(95)00820-9 10.1016/S1053-0770(05)80005-9 10.1016/S1010-7940(96)80266-1 10.1016/S0022-5223(95)70023-4 10.1016/S1010-7940(96)80265-X 10.1111/j.1749-6632.1987.tb33034.x 10.1016/S0022-5223(96)70384-7 10.1161/01.CIR.92.9.2579 10.3109/14017439209099075 10.1016/0003-4975(96)00492-4 10.1111/j.1525-1594.1996.tb04588.x 10.1038/268358a0 10.1111/j.1399-6576.1996.tb04438.x 10.1111/j.1525-1594.1997.tb03740.x 10.1016/0003-4975(95)00482-Z 10.1016/1053-0770(94)90066-3 10.1111/j.1540-8191.1996.tb00018.x 10.1016/S0003-4975(96)01054-5 10.1097/00002480-199407000-00073 10.1016/S0003-4975(98)00223-9 10.3109/10731198309118804 10.1016/0003-4975(95)00777-I 10.1016/S1053-0770(97)90108-7 10.1055/s-0038-1649568 10.1097/00002480-199407000-00118 10.1016/0003-4975(95)01199-4 10.1182/blood.V82.11.3350.3350 10.1177/026765919601100406 10.1016/S1010-7940(96)80114-X 10.1016/S0003-4975(97)00088-X 10.1016/S0003-4975(96)00942-3 10.1111/j.1525-1594.1996.tb04573.x 10.1016/S1010-7940(97)88351-0 10.1111/j.1525-1594.1997.tb03753.x 10.1177/039139889401700507 10.1016/S0003-4975(96)01099-5 10.1016/0003-4975(95)00763-6 10.3109/14017439409098703 10.1016/S0022-5223(97)70124-7 10.1002/ajh.2830480412 10.3109/14017439509107225 10.1016/S1010-7940(96)01062-7 10.1007/BF01732874 10.1055/s-2007-1013716 10.1046/j.1365-2141.1998.00723.x 10.1016/0003-4975(94)90736-6 10.1111/j.1365-2141.1996.tb08989.x 10.1016/S0003-4975(98)00156-8 10.1016/0003-4975(96)00249-4 10.1111/j.1525-1594.1996.tb04538.x |
ContentType | Journal Article |
Copyright | Elsevier Science B.V. 1999 1999 INIST-CNRS |
Copyright_xml | – notice: Elsevier Science B.V. 1999 – notice: 1999 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/S1010-7940(99)00210-9 |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1873-734X |
EndPage | 350 |
ExternalDocumentID | 10_1016_S1010_7940_99_00210_9 10554855 1986235 10.1016/S1010-7940(99)00210-9 ark_67375_HXZ_FHTMDXBS_Q |
Genre | Journal Article Review |
GroupedDBID | --- --K .2P .I3 .ZR 0R~ 1B1 1TH 29G 4.4 48X 53G 5GY 5RE 5WD 71M AABZA AACZT AAJKP AAJQQ AAKAS AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWDT ABEJV ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABSAR ABSMQ ABWST ABXVV ABZBJ ACCCW ACFRR ACGFS ACUFI ACUTJ ACUTO ACYHN ACZBC ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZCM ADZXQ AEGPL AEJOX AEKER AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AFYAG AGINJ AGKRT AGMDO AGQXC AGSYK AGUTN AHXPO AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH AQDSO AQKUS ASPBG ATGXG ATTQO AVNTJ AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BSCLL BTRTY BVRKM BZKNY C45 CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EIHJH EJD EMOBN ENERS EO8 EO9 EP2 EP3 F5P F9B FECEO FEDTE FLUFQ FNPLU FOEOM FOTVD FQBLK G-Q GAUVT GJXCC H13 H5~ HAR HVGLF HW0 HZ~ IHE J21 J5H KBUDW KOP KSI KSN M27 M41 MBLQV MHKGH N9A NGC NOMLY NOYVH NQ- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF OZT O~Y P2P PAFKI PB- PEELM Q1. Q5Y RD5 RIG ROL ROX ROZ RPZ RUSNO RW1 RXO SDG SDH SV3 TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 AASNB AABJS AABMN AAESY AAIYJ AANRK AAPBV ABPTK ACIMA ADEIU ADORX ADQLU AIKOY AIMBJ ALXQX ASMCH AWCFO AZQFJ BGYMP BYORX CASEJ DPORF DPPUQ IQODW OBFPC CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c613t-69bd235d3a9fe9b61bb0eac2dc578884d1d5fc2b41275dd970161cf237734a103 |
ISSN | 1010-7940 |
IngestDate | Fri Oct 25 10:49:13 EDT 2024 Thu Sep 12 17:38:11 EDT 2024 Wed Oct 16 00:50:33 EDT 2024 Sun Oct 29 17:11:01 EDT 2023 Wed Aug 28 03:23:42 EDT 2024 Wed Oct 30 09:48:26 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Hemocompatibility Heparin-coating Extracorporeal circulation Cardiopulmonary bypass Human Anesthesia Instrumentation Anticoagulant Heparin Technique Compatibility Coated material Bibliographic review Blood |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c613t-69bd235d3a9fe9b61bb0eac2dc578884d1d5fc2b41275dd970161cf237734a103 |
Notes | PII:S1010794099002109 ark:/67375/HXZ-FHTMDXBS-Q istex:78317D287E7C94783CEC0A02D5BEC53208D347FB ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
OpenAccessLink | https://academic.oup.com/ejcts/article-pdf/16/3/342/1298571/16-3-342.pdf |
PMID | 10554855 |
PQID | 69246013 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_69246013 crossref_primary_10_1016_S1010_7940_99_00210_9 pubmed_primary_10554855 pascalfrancis_primary_1986235 oup_primary_10_1016_S1010-7940_99_00210-9 istex_primary_ark_67375_HXZ_FHTMDXBS_Q |
PublicationCentury | 1900 |
PublicationDate | 1999-09-01 |
PublicationDateYYYYMMDD | 1999-09-01 |
PublicationDate_xml | – month: 09 year: 1999 text: 1999-09-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Amsterdam |
PublicationPlace_xml | – name: Amsterdam – name: Germany |
PublicationTitle | European journal of cardio-thoracic surgery |
PublicationTitleAbbrev | Eur J Cardiothorac Surg |
PublicationTitleAlternate | Eur J Cardiothorac Surg |
PublicationYear | 1999 |
Publisher | Elsevier Science B.V Elsevier Science |
Publisher_xml | – name: Elsevier Science B.V – name: Elsevier Science |
References | Muehrcke (10.1016/S1010-7940(99)00210-9_BIB90) 1996; 112 Bozdayi (10.1016/S1010-7940(99)00210-9_BIB45) 1996; 20 Ovrum (10.1016/S1010-7940(99)00210-9_BIB18) 1995; 92 Von Segesser (10.1016/S1010-7940(99)00210-9_BIB71) 1993; 39 Elgue (10.1016/S1010-7940(99)00210-9_BIB36) 1993; 70 Gott (10.1016/S1010-7940(99)00210-9_BIB8) 1963; 142 Bannan (10.1016/S1010-7940(99)00210-9_BIB25) 1997; 63 te Velthuis (10.1016/S1010-7940(99)00210-9_BIB53) 1996; 61 Weiss (10.1016/S1010-7940(99)00210-9_BIB79) 1996; 10 Muehrcke (10.1016/S1010-7940(99)00210-9_BIB72) 1995; 110 Ranucci (10.1016/S1010-7940(99)00210-9_BIB55) 1996; 61 Ovrum (10.1016/S1010-7940(99)00210-9_BIB20) 1995; 60 Ernofsson (10.1016/S1010-7940(99)00210-9_BIB81) 1995; 29 Borowiec (10.1016/S1010-7940(99)00210-9_BIB15) 1992; 97 Moen (10.1016/S1010-7940(99)00210-9_BIB47) 1995; 60 Matheis (10.1016/S1010-7940(99)00210-9_BIB62) 1996 Jansen (10.1016/S1010-7940(99)00210-9_BIB35) 1995; 110 Baba (10.1016/S1010-7940(99)00210-9_BIB49) 1997; 21 Yamanaka (10.1016/S1010-7940(99)00210-9_BIB54) 1996; 44 Colman (10.1016/S1010-7940(99)00210-9_BIB33) 1987 Gorman (10.1016/S1010-7940(99)00210-9_BIB76) 1996; 111 Hamulu (10.1016/S1010-7940(99)00210-9_BIB87) 1996; 11 Müller (10.1016/S1010-7940(99)00210-9_BIB3) 1991; 4 Ovrum (10.1016/S1010-7940(99)00210-9_BIB43) 1995; 110 Wan (10.1016/S1010-7940(99)00210-9_BIB30) 1997; 112 Bannan (10.1016/S1010-7940(99)00210-9_BIB5) 1998; 101 Horimoto (10.1016/S1010-7940(99)00210-9_BIB52) 1996; 20 Larsson (10.1016/S1010-7940(99)00210-9_BIB63) 1987; 516 Vroman (10.1016/S1010-7940(99)00210-9_BIB28) 1998; 64 Von Segesser (10.1016/S1010-7940(99)00210-9_BIB21) 1992; 103 Korn (10.1016/S1010-7940(99)00210-9_BIB38) 1996; 111 Ovrum (10.1016/S1010-7940(99)00210-9_BIB42) 1996; 10 Borowiec (10.1016/S1010-7940(99)00210-9_BIB77) 1995; 29 10.1016/S1010-7940(99)00210-9_BIB1 Marcum (10.1016/S1010-7940(99)00210-9_BIB7) 1989 Lundblad (10.1016/S1010-7940(99)00210-9_BIB48) 1997; 63 Campbell (10.1016/S1010-7940(99)00210-9_BIB68) 1994; 40 Von Segesser (10.1016/S1010-7940(99)00210-9_BIB67) 1994; 17 Mahoney (10.1016/S1010-7940(99)00210-9_BIB26) 1988; 13 Aldea (10.1016/S1010-7940(99)00210-9_BIB17) 1996; 11 Ovrum (10.1016/S1010-7940(99)00210-9_BIB80) 1996; 10 Borowiec (10.1016/S1010-7940(99)00210-9_BIB75) 1997; 45 Hsu (10.1016/S1010-7940(99)00210-9_BIB12) 1997; 11 Borowiec (10.1016/S1010-7940(99)00210-9_BIB24) 1992; 26 Chapman (10.1016/S1010-7940(99)00210-9_BIB65) 1987; 15 Yamada (10.1016/S1010-7940(99)00210-9_BIB84) 1996; 40 Tsai (10.1016/S1010-7940(99)00210-9_BIB69) 1994; 40 Gu (10.1016/S1010-7940(99)00210-9_BIB70) 1998; 65 Hendrikx (10.1016/S1010-7940(99)00210-9_BIB73) 1997; 20 Svenmarker (10.1016/S1010-7940(99)00210-9_BIB44) 1997; 11 Moen (10.1016/S1010-7940(99)00210-9_BIB37) 1996; 62 Kagisaki (10.1016/S1010-7940(99)00210-9_BIB41) 1997; 21 Akihiko (10.1016/S1010-7940(99)00210-9_BIB50) 1997; 21 van der Kamp (10.1016/S1010-7940(99)00210-9_BIB59) 1997; 20 Barstad (10.1016/S1010-7940(99)00210-9_BIB89) 1996; 94 Belboul (10.1016/S1010-7940(99)00210-9_BIB74) 1997; 12 Colman (10.1016/S1010-7940(99)00210-9_BIB4) 1995; 48 Yianni (10.1016/S1010-7940(99)00210-9_BIB66) 1992 Aldea (10.1016/S1010-7940(99)00210-9_BIB22) 1998; 65 Fuhrer (10.1016/S1010-7940(99)00210-9_BIB32) 1990; 61 Fosse (10.1016/S1010-7940(99)00210-9_BIB85) 1997; 11 Moen (10.1016/S1010-7940(99)00210-9_BIB29) 1997; 63 Didisheim (10.1016/S1010-7940(99)00210-9_BIB31) 1989 Palatianos (10.1016/S1010-7940(99)00210-9_BIB51) 1991; 37 Aldea (10.1016/S1010-7940(99)00210-9_BIB23) 1996; 62 Ernofsson (10.1016/S1010-7940(99)00210-9_BIB86) 1997; 113 Baufreton (10.1016/S1010-7940(99)00210-9_BIB6) 1997; 63 Gravlee (10.1016/S1010-7940(99)00210-9_BIB10) 1994; 8 Tkebuchava (10.1016/S1010-7940(99)00210-9_BIB58) 1996; 1 Pekna (10.1016/S1010-7940(99)00210-9_BIB19) 1994; 28 Wildevuur (10.1016/S1010-7940(99)00210-9_BIB56) 1997; 11 Wendel (10.1016/S1010-7940(99)00210-9_BIB57) 1992 Steinberg (10.1016/S1010-7940(99)00210-9_BIB78) 1995; 60 Wahba (10.1016/S1010-7940(99)00210-9_BIB13) 1998; 65 Kuitunen (10.1016/S1010-7940(99)00210-9_BIB16) 1997; 63 Taylor (10.1016/S1010-7940(99)00210-9_BIB2) 1996; 61 Wagner (10.1016/S1010-7940(99)00210-9_BIB39) 1994; 58 Fraedrich (10.1016/S1010-7940(99)00210-9_BIB60) 1995 Janvier (10.1016/S1010-7940(99)00210-9_BIB11) 1996; 62 Hogevold (10.1016/S1010-7940(99)00210-9_BIB46) 1997; 12 Von Segesser (10.1016/S1010-7940(99)00210-9_BIB14) 1994; 58 Fukutomi (10.1016/S1010-7940(99)00210-9_BIB40) 1996; 20 Spiess (10.1016/S1010-7940(99)00210-9_BIB82) 1998; 12 Saenz (10.1016/S1010-7940(99)00210-9_BIB83) 1996; 10 Zwaal (10.1016/S1010-7940(99)00210-9_BIB64) 1977; 268 Ovrum (10.1016/S1010-7940(99)00210-9_BIB91) 1995; 60 Boisclair (10.1016/S1010-7940(99)00210-9_BIB27) 1993; 82 Larm (10.1016/S1010-7940(99)00210-9_BIB9) 1983; 11 te Velthuis (10.1016/S1010-7940(99)00210-9_BIB88) 1997; 114 Mammen (10.1016/S1010-7940(99)00210-9_BIB34) 1990; 2 Knobl (10.1016/S1010-7940(99)00210-9_BIB61) 1995 |
References_xml | – volume: 103 start-page: 790 year: 1992 ident: 10.1016/S1010-7940(99)00210-9_BIB21 article-title: Reduction and elimination of systemic heparinization during cardiopulmonary bypass publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(19)34964-5 contributor: fullname: Von Segesser – volume: 65 start-page: 425 year: 1998 ident: 10.1016/S1010-7940(99)00210-9_BIB22 article-title: Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits publication-title: Ann Thorac Surg doi: 10.1016/S0003-4975(97)01347-7 contributor: fullname: Aldea – volume: 20 start-page: 43 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB59 article-title: Blood interaction with a Bioline heparin coated HIA-VAD: a study on calves publication-title: Int J Artif Organs doi: 10.1177/039139889702000109 contributor: fullname: van der Kamp – volume: 112 start-page: 472 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB90 article-title: Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(96)70275-1 contributor: fullname: Muehrcke – volume: 61 start-page: 1607 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB2 article-title: SIRS – the systemic inflammatory response syndrome after cardiac operations publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(96)00225-1 contributor: fullname: Taylor – volume: 63 start-page: 50 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB6 article-title: Heparin coating with aprotinin reduces blood activation during coronary artery operations publication-title: Ann Thorac Surg doi: 10.1016/S0003-4975(96)00964-2 contributor: fullname: Baufreton – volume: 29 start-page: 157 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB81 article-title: Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits publication-title: Scand J Thorac Cardiovasc Surg doi: 10.3109/14017439509107224 contributor: fullname: Ernofsson – volume: 97 start-page: 55 year: 1992 ident: 10.1016/S1010-7940(99)00210-9_BIB15 article-title: Heparin-coated cardiopulmonary bypass circuits and 25% reduction of heparin dose in coronary artery surgery – a clinical study publication-title: Ups J Med Sci doi: 10.3109/03009739209179282 contributor: fullname: Borowiec – volume: 11 start-page: 616 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB56 article-title: Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version) publication-title: The European working group on heparin coated extracorporeal circulation circuits. Eur J Cardiothorac Surg contributor: fullname: Wildevuur – volume: 112 start-page: 676 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB30 article-title: Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies publication-title: Chest doi: 10.1378/chest.112.3.676 contributor: fullname: Wan – volume: 111 start-page: 1 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB76 article-title: Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(96)70395-1 contributor: fullname: Gorman – volume: 110 start-page: 829 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB35 article-title: Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(95)70117-6 contributor: fullname: Jansen – volume: 110 start-page: 843 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB72 article-title: Complications of extracorporeal life support systems using heparin-bound surfaces publication-title: The risk of intracardiac clot formation. J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(95)70119-2 contributor: fullname: Muehrcke – volume: 13 start-page: 192 year: 1988 ident: 10.1016/S1010-7940(99)00210-9_BIB26 article-title: Heparin-bonded circuits: clinical outcomes and costs publication-title: Perfusion doi: 10.1177/026765919801300307 contributor: fullname: Mahoney – volume: 60 start-page: 365 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB91 article-title: Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(95)00366-S contributor: fullname: Ovrum – volume: 12 start-page: 299 year: 1998 ident: 10.1016/S1010-7940(99)00210-9_BIB82 article-title: Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery publication-title: J Cardiothorac Vasc Anesth doi: 10.1016/S1053-0770(98)90010-6 contributor: fullname: Spiess – volume: 142 start-page: 1297 year: 1963 ident: 10.1016/S1010-7940(99)00210-9_BIB8 article-title: Heparin bonding on colloidal graphite surfaces publication-title: Science doi: 10.1126/science.142.3597.1297 contributor: fullname: Gott – volume: 1 start-page: 36 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB58 article-title: Thrombosis-resistant heparin-coated diffusion membrane oxygenators: an experimental study publication-title: Swiss Surg Suppl contributor: fullname: Tkebuchava – start-page: 187 year: 1992 ident: 10.1016/S1010-7940(99)00210-9_BIB66 article-title: Biocompatible surfaces based upon biomembrane mimicry contributor: fullname: Yianni – volume: 12 start-page: 385 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB74 article-title: Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery publication-title: Perfusion doi: 10.1177/026765919701200607 contributor: fullname: Belboul – volume: 39 start-page: M190 year: 1993 ident: 10.1016/S1010-7940(99)00210-9_BIB71 article-title: Can protamine be used during perfusion with heparin surface coated equipment? publication-title: ASAIO J doi: 10.1097/00002480-199339030-00008 contributor: fullname: Von Segesser – volume: 63 start-page: 105 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB29 article-title: Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass publication-title: Ann Thorac Surg doi: 10.1016/S0003-4975(96)00743-6 contributor: fullname: Moen – start-page: 275 year: 1989 ident: 10.1016/S1010-7940(99)00210-9_BIB31 article-title: Thromboembolic complications of cardiovascular devices and artificial surfaces contributor: fullname: Didisheim – volume: 21 start-page: 779 issue: 7 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB49 article-title: Experimental studies on three types of heparin-coated cardiopulmonary circuits publication-title: Artificial Organs doi: 10.1111/j.1525-1594.1997.tb03741.x contributor: fullname: Baba – volume: 20 start-page: 166 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB73 article-title: The use of a heparin removal device: a valid alternative to protamine publication-title: Int J Artif Organs doi: 10.1177/039139889702000308 contributor: fullname: Hendrikx – volume: 113 start-page: 576 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB86 article-title: Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(97)70373-8 contributor: fullname: Ernofsson – volume: 58 start-page: 391 year: 1994 ident: 10.1016/S1010-7940(99)00210-9_BIB14 article-title: Risk and benefit of low systemic heparinization during open heart operations publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(94)92213-6 contributor: fullname: Von Segesser – volume: 61 start-page: 76 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB55 article-title: Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(95)00820-9 contributor: fullname: Ranucci – volume: 10 start-page: 464 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB79 article-title: Perioperative course and recovery after heparin-coated cardiopulmonary bypass: low-dose versus high-dose heparin management publication-title: J Cardiothorac Vasc Anesth doi: 10.1016/S1053-0770(05)80005-9 contributor: fullname: Weiss – volume: 10 start-page: 54 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB42 article-title: Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation publication-title: Eur J Cardiothorac Surg doi: 10.1016/S1010-7940(96)80266-1 contributor: fullname: Ovrum – volume: 110 start-page: 1623 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB43 article-title: Complement and granulocyte activation in two different types of heparinized extracorporeal circuits publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(95)70023-4 contributor: fullname: Ovrum – volume: 44 start-page: 47 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB54 article-title: The evaluation of the bio-compatibility and the clinical usefulness of heparin-coated cardiopulmonary bypass circuits publication-title: Nippon Kyobu Geka Gakkai Zasshi contributor: fullname: Yamanaka – volume: 10 start-page: 48 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB83 article-title: Heparin-coated circuit in coronary surgery publication-title: A clinical study. Eur J Cardiothorac Surg doi: 10.1016/S1010-7940(96)80265-X contributor: fullname: Saenz – volume: 2 start-page: 31 year: 1990 ident: 10.1016/S1010-7940(99)00210-9_BIB34 article-title: Contact activation: the interaction of clotting, fibrinolytic, kinin and complement systems publication-title: Biomedical Progress contributor: fullname: Mammen – volume: 516 start-page: 102 year: 1987 ident: 10.1016/S1010-7940(99)00210-9_BIB63 article-title: The search for thromboresistance using immobilized heparin publication-title: Ann NY Acad Sci doi: 10.1111/j.1749-6632.1987.tb33034.x contributor: fullname: Larsson – volume: 111 start-page: 1073 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB38 article-title: The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(96)70384-7 contributor: fullname: Korn – volume: 92 start-page: 2579 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB18 article-title: Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass publication-title: Circulation doi: 10.1161/01.CIR.92.9.2579 contributor: fullname: Ovrum – volume: 26 start-page: 177 year: 1992 ident: 10.1016/S1010-7940(99)00210-9_BIB24 article-title: Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose publication-title: Scand J Thorac Cardiovasc Surg doi: 10.3109/14017439209099075 contributor: fullname: Borowiec – volume: 62 start-page: 1134 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB37 article-title: Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(96)00492-4 contributor: fullname: Moen – start-page: 275 year: 1989 ident: 10.1016/S1010-7940(99)00210-9_BIB7 article-title: The biochemistry, cell biology, and pathophysiology of anticoagulantly heparin-like molecules of the vessel wall contributor: fullname: Marcum – start-page: 253 year: 1987 ident: 10.1016/S1010-7940(99)00210-9_BIB33 article-title: Initiation of blood coagulation at artificial surfaces contributor: fullname: Colman – volume: 20 start-page: 1008 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB45 article-title: Effects of heparin coating of cardiopulmonary bypass circuits on in vitro oxygen free radical production during coronary bypass surgery publication-title: Artif Organs doi: 10.1111/j.1525-1594.1996.tb04588.x contributor: fullname: Bozdayi – volume: 268 start-page: 358 year: 1977 ident: 10.1016/S1010-7940(99)00210-9_BIB64 article-title: Membrane assymmetry and blood coagulation publication-title: Nature doi: 10.1038/268358a0 contributor: fullname: Zwaal – volume: 40 start-page: 311 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB84 article-title: Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass publication-title: Acta Anaesthesiol Scand doi: 10.1111/j.1399-6576.1996.tb04438.x contributor: fullname: Yamada – volume: 21 start-page: 772 issue: 7 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB50 article-title: A clinical study for the durability of oxygenators on cardiopulmonary support publication-title: Artificial Organs doi: 10.1111/j.1525-1594.1997.tb03740.x contributor: fullname: Akihiko – volume: 60 start-page: 525 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB78 article-title: Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(95)00482-Z contributor: fullname: Steinberg – volume: 8 start-page: 213 year: 1994 ident: 10.1016/S1010-7940(99)00210-9_BIB10 article-title: Heparin-coated cardiopulmonary bypass circuits publication-title: J Cardiothorac Vasc Anesth doi: 10.1016/1053-0770(94)90066-3 contributor: fullname: Gravlee – volume: 11 start-page: 85 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB17 article-title: Enhanced blood conservation in primary coronary artery bypass surgery using heparin-bonded circuits with lower anticoagulation publication-title: J Card Surg doi: 10.1111/j.1540-8191.1996.tb00018.x contributor: fullname: Aldea – start-page: 47 year: 1992 ident: 10.1016/S1010-7940(99)00210-9_BIB57 article-title: Kardiopulmonaler Bypass unter Verzicht von Antikoagulantien? – Ex-vivo-Modelluntersuchungen mit Verwendung eines heparinbeschichteten Membranoxygenators contributor: fullname: Wendel – volume: 63 start-page: 663 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB25 article-title: Low heparinization with heparin-bonded bypass circuits: is it a safe strategy? publication-title: Ann Thorac Surg doi: 10.1016/S0003-4975(96)01054-5 contributor: fullname: Bannan – volume: 40 start-page: M619 year: 1994 ident: 10.1016/S1010-7940(99)00210-9_BIB69 article-title: Surface modifying additives for improved device-blood compatibility publication-title: ASAIO J doi: 10.1097/00002480-199407000-00073 contributor: fullname: Tsai – volume: 65 start-page: 1342 year: 1998 ident: 10.1016/S1010-7940(99)00210-9_BIB70 article-title: Cardiopulmonary bypass circuit treated with surface-modifying additives: a clinical evaluation of blood compatibility publication-title: Ann Thorac Surg doi: 10.1016/S0003-4975(98)00223-9 contributor: fullname: Gu – volume: 11 start-page: 161 year: 1983 ident: 10.1016/S1010-7940(99)00210-9_BIB9 article-title: A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue publication-title: Biomater Med Devices Artif Organs doi: 10.3109/10731198309118804 contributor: fullname: Larm – volume: 60 start-page: 1317 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB47 article-title: Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(95)00777-I contributor: fullname: Moen – volume: 11 start-page: 376 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB12 article-title: Biocompatibility in cardiopulmonary bypass publication-title: J Cardiothorac Vasc Anesth doi: 10.1016/S1053-0770(97)90108-7 contributor: fullname: Hsu – volume: 70 start-page: 289 year: 1993 ident: 10.1016/S1010-7940(99)00210-9_BIB36 article-title: On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin publication-title: Thromb Haemost doi: 10.1055/s-0038-1649568 contributor: fullname: Elgue – volume: 40 start-page: 853 year: 1994 ident: 10.1016/S1010-7940(99)00210-9_BIB68 article-title: Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer publication-title: ASAIO J doi: 10.1097/00002480-199407000-00118 contributor: fullname: Campbell – volume: 61 start-page: 1153 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB53 article-title: Specific complement inhibition with heparin-coated extracorporeal circuits publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(95)01199-4 contributor: fullname: te Velthuis – volume: 82 start-page: 3350 year: 1993 ident: 10.1016/S1010-7940(99)00210-9_BIB27 article-title: Mechanisms of thrombin generation during surgery and cardiopulmonary bypass publication-title: Blood doi: 10.1182/blood.V82.11.3350.3350 contributor: fullname: Boisclair – volume: 11 start-page: 333 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB87 article-title: Complement consumption during cardiopulmonary bypass: comparison of Duraflo II heparin-coated and uncoated circuits in fully heparinized patients publication-title: Perfusion doi: 10.1177/026765919601100406 contributor: fullname: Hamulu – volume: 10 start-page: 449 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB80 article-title: Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis publication-title: Eur J Cardiothorac Surg doi: 10.1016/S1010-7940(96)80114-X contributor: fullname: Ovrum – volume: 63 start-page: 1361 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB48 article-title: Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass publication-title: Ann Thorac Surg doi: 10.1016/S0003-4975(97)00088-X contributor: fullname: Lundblad – volume: 62 start-page: 1926 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB11 article-title: Extracorporeal circulation, hemocompatibility, and biomaterials publication-title: Ann Thorac Surg doi: 10.1016/S0003-4975(96)00942-3 contributor: fullname: Janvier – volume: 20 start-page: 936 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB52 article-title: Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery publication-title: Artif Organs doi: 10.1111/j.1525-1594.1996.tb04573.x contributor: fullname: Horimoto – volume: 11 start-page: 957 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB44 article-title: Clinical effects of the heparin coated surface in cardiopulmonary bypass publication-title: Eur J Cardiothorac Surg doi: 10.1016/S1010-7940(97)88351-0 contributor: fullname: Svenmarker – volume: 64 start-page: 352 year: 1998 ident: 10.1016/S1010-7940(99)00210-9_BIB28 article-title: The life of an artificial device in contact with blood: initial events and their effect on its final state publication-title: Bull NY Acad Med contributor: fullname: Vroman – volume: 21 start-page: 836 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB41 article-title: Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass publication-title: Artif Organs doi: 10.1111/j.1525-1594.1997.tb03753.x contributor: fullname: Kagisaki – volume: 17 start-page: 294 year: 1994 ident: 10.1016/S1010-7940(99)00210-9_BIB67 article-title: Evaluation of phospholipidic surface coatings ex-vivo publication-title: Int J Artif Organs doi: 10.1177/039139889401700507 contributor: fullname: Von Segesser – volume: 63 start-page: 438 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB16 article-title: Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation publication-title: Ann Thorac Surg doi: 10.1016/S0003-4975(96)01099-5 contributor: fullname: Kuitunen – volume: 60 start-page: 1755 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB20 article-title: High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(95)00763-6 contributor: fullname: Ovrum – volume: 28 start-page: 5 year: 1994 ident: 10.1016/S1010-7940(99)00210-9_BIB19 article-title: Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass publication-title: Scand J Thorac Cardiovasc Surg doi: 10.3109/14017439409098703 contributor: fullname: Pekna – start-page: 44 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB62 article-title: Heparin-coated cardiopulmonary bypass is associated with reduced pulmonary and cerebral injury (Abstract 185) publication-title: Thorac Cardiovasc Surg contributor: fullname: Matheis – volume: 114 start-page: 117 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB88 article-title: Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(97)70124-7 contributor: fullname: te Velthuis – volume: 15 start-page: 475 year: 1987 ident: 10.1016/S1010-7940(99)00210-9_BIB65 article-title: Dynamics and structure of biomembranes publication-title: Biochem Soc Trans contributor: fullname: Chapman – volume: 48 start-page: 267 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB4 article-title: Hemostatic complications of cardiopulmonary bypass publication-title: Am J Hematol doi: 10.1002/ajh.2830480412 contributor: fullname: Colman – volume: 29 start-page: 167 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB77 article-title: Circulating cytokines and granulocyte-derived enzymes during complex heart surgery. A clinical study with special reference to heparin-coating of cardiopulmonary bypass circuits publication-title: Scand J Thorac Cardiovasc Surg 1995 doi: 10.3109/14017439509107225 contributor: fullname: Borowiec – volume: 11 start-page: 320 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB85 article-title: Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study publication-title: Eur J Cardiothorac Surg doi: 10.1016/S1010-7940(96)01062-7 contributor: fullname: Fosse – volume: 61 start-page: 258 year: 1990 ident: 10.1016/S1010-7940(99)00210-9_BIB32 article-title: F XII (Review) publication-title: Blut doi: 10.1007/BF01732874 contributor: fullname: Fuhrer – year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB60 article-title: A new covalent heparin bonding process of extracorporeal circuits improves the hemocompatibility of cardiopulmonary bypass (Abstract 112) publication-title: CREF contributor: fullname: Fraedrich – volume: 45 start-page: 163 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB75 article-title: Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits publication-title: Thorac Cardiovasc Surg doi: 10.1055/s-2007-1013716 contributor: fullname: Borowiec – volume: 4 start-page: 3 year: 1991 ident: 10.1016/S1010-7940(99)00210-9_BIB3 article-title: Adult respiratory distress syndrome (ARDS): activation of complement, coagulation and fibrinolytic systems publication-title: Biomedical Progress contributor: fullname: Müller – ident: 10.1016/S1010-7940(99)00210-9_BIB1 – volume: 101 start-page: 455 year: 1998 ident: 10.1016/S1010-7940(99)00210-9_BIB5 article-title: Aprotinin complements heparin bonding in an in vitro model of cardiopulmonary bypass publication-title: Br J Haematol doi: 10.1046/j.1365-2141.1998.00723.x contributor: fullname: Bannan – volume: 58 start-page: 734 year: 1994 ident: 10.1016/S1010-7940(99)00210-9_BIB39 article-title: Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(94)90736-6 contributor: fullname: Wagner – volume: 94 start-page: 517 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB89 article-title: Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit publication-title: Br J Haematol doi: 10.1111/j.1365-2141.1996.tb08989.x contributor: fullname: Barstad – volume: 65 start-page: 1310 year: 1998 ident: 10.1016/S1010-7940(99)00210-9_BIB13 article-title: Heparin-coated equipment reduces the risk of oxygenator failure publication-title: Ann Thorac Surg doi: 10.1016/S0003-4975(98)00156-8 contributor: fullname: Wahba – volume: 62 start-page: 410 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB23 article-title: Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(96)00249-4 contributor: fullname: Aldea – volume: 37 start-page: 620 year: 1991 ident: 10.1016/S1010-7940(99)00210-9_BIB51 article-title: Platelet preservation during cardiopulmonary bypass with iloprost and Duraflo-II heparin-coated surfaces publication-title: ASAIO Trans contributor: fullname: Palatianos – start-page: 24 year: 1995 ident: 10.1016/S1010-7940(99)00210-9_BIB61 article-title: Erste klinische Erfahrungen mit der Bioline Coating-Beschichtung bei Säuglingen und Kleinkindern mit kongenitalen Vitien – Beschichtung des extracorporalen Systems (Abstract) publication-title: Int T Ges Kardiotech contributor: fullname: Knobl – volume: 20 start-page: 767 year: 1996 ident: 10.1016/S1010-7940(99)00210-9_BIB40 article-title: Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment publication-title: Artif Organs doi: 10.1111/j.1525-1594.1996.tb04538.x contributor: fullname: Fukutomi – volume: 12 start-page: 9 year: 1997 ident: 10.1016/S1010-7940(99)00210-9_BIB46 article-title: Effects of heparin coating on the expression of CD11b publication-title: CD11c and CD62L by leucocytes in extracorporeal circulation in vitro. Perfusion contributor: fullname: Hogevold |
SSID | ssj0006327 |
Score | 2.1211267 |
SecondaryResourceType | review_article |
Snippet | Objective: Extracorporeal circulation procedures have been shown to induce complement and leukocyte activation, release of endotoxin and inflammatory... Extracorporeal circulation procedures have been shown to induce complement and leukocyte activation, release of endotoxin and inflammatory mediators, including... OBJECTIVEExtracorporeal circulation procedures have been shown to induce complement and leukocyte activation, release of endotoxin and inflammatory mediators,... |
SourceID | proquest crossref pubmed pascalfrancis oup istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 342 |
SubjectTerms | Anesthesia Anesthesia depending on type of surgery Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Animals Anticoagulants - chemistry Biological and medical sciences Blood Physiological Phenomena Coated Materials, Biocompatible Coronary Disease - surgery Equipment Design Equipment Safety Extracorporeal circulation Extracorporeal Circulation - instrumentation Extracorporeal Circulation - methods Hemocompatibility Heparin - chemistry Heparin-coating Humans Materials Testing Medical sciences Sensitivity and Specificity Thoracic and cardiovascular surgery. Cardiopulmonary bypass |
Title | Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation |
URI | https://api.istex.fr/ark:/67375/HXZ-FHTMDXBS-Q/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/10554855 https://search.proquest.com/docview/69246013 |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxNBFB5iCyKIeDdqdR6sWMrUZGcvmUdtrVGJIE0h9GXYuSwN0mxJNlD8Tf5Iz1x2dmMaqL4sYUlmhnzfnMucyyD0RsWxKmgeE6WEJGDfMiJElpD-QILy06nq5SaiO_qeDk_jr5Nk0un8bmUtLStxIH9dW1fyP6jCO8DVVMn-A7JhUHgBnwFfeALC8LwRxodlbrKWSWjEats1TO05gbYm5bm-KG2aeeWyYG083YzkG0cobSXF_nIBhqft_n1VzUFImvbGpuWwnM6lv-Br4xm-t2elzWwl1TmQSk7l_qJVcG1DPzPlMgKGoB1X84LPptpf4vJZz-s6f3cW4foXsPZZRCiSqeVSKJaxstXE3WH7uzCMdu8GGSUZdUmaQSCnLeLRlnSlrhGXV9TUdaxd0wHuOOIkTLdrfMrdiFn3lrBG8dXB_r_0YchSzOc_TdpblvDh5IwfD8ejo8nHE_7jFtqOQKyZBMKjL9-C3k-pvSA4zNvUi71vFvOOsT2_kBVLaNts6qu6yvLuZb6ALVq4u1U2Oz_WCBrfR_e894I_OCo-QB09e4huj3x-xiN0sc5IXJXYMxIDI_EaI3FZ4IaR2DMSG0ZiYCReZSRuMfIxOj3-ND4cEn-hB5FgNVYkZUJFNFE0Z4VmIu0L0QPFHymZmJOYWPVVUshIxObWAaVYZvwRWUQ0A4rk_R59grZm5Uw_QziPB0mU9VgkwKEXWjNgQ0GLKAYD2MSsuuig_nP5pevbwkNCo0GDGzQ4Y9yiwVkXvbUQhG9vQr-L9gCj6wclK4MSGHRnBcnmV2wAfkfSRa9rZDmIdROry2e6XC54yqI4Bfesi546wFsTggcwSJLnN13wC3Sn2asv0VY1X-odsKQr8coS-A95kchq |
link.rule.ids | 315,783,787,27938,27939 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Coating-techniques+to+improve+the+hemocompatibility+of+artificial+devices+used+for+extracorporeal+circulation&rft.jtitle=European+journal+of+cardio-thoracic+surgery&rft.au=Wendel%2C+Hans+Peter&rft.au=Ziemer%2C+Gerhard&rft.date=1999-09-01&rft.pub=Elsevier+Science+B.V&rft.issn=1010-7940&rft.eissn=1873-734X&rft.volume=16&rft.issue=3&rft.spage=342&rft.epage=350&rft_id=info:doi/10.1016%2FS1010-7940%2899%2900210-9&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_HXZ_FHTMDXBS_Q |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1010-7940&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1010-7940&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1010-7940&client=summon |